XOMA Corporation XOMA Business Segments — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by XOMA Corporation in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about XOMA Corporation's business segments — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is XOMA Corporation's business segments — research and development expense?
- XOMA Corporation (XOMA) reported business segments — research and development expense of $49K in Q1 2026.
- How has XOMA Corporation's business segments — research and development expense changed year-over-year?
- XOMA Corporation's business segments — research and development expense decreased by 96.2% year-over-year, from $1.29M to $49K.
- What is the long-term trend for XOMA Corporation's business segments — research and development expense?
- Over 2 years (2023 to 2025), XOMA Corporation's business segments — research and development expense has grown at a 246.0% compound annual growth rate (CAGR), from $143K to $1.71M.
- What does business segments — research and development expense mean?
- Reflects costs associated with the ongoing monitoring or potential development support of therapeutic candidates within the royalty portfolio. While the company primarily acts as a royalty aggregator, these expenses indicate active oversight or residual obligations related to the underlying biotech assets.